The Life at Sussex Healthcare

Sussex Healthcare began in 1985 to provide residence to the old. The old people who want to enjoy life to the fullest and are seeking the professional companion and medical attention have a place at Sussex. The institution reaches out to the whole of Sussex by providing more than 23 living homes scattered around. The houses have more than 500-bed spaces. We have nurses in all the units who attend to the needs of every patient at all time. Also, each home has a qualified chef with a determined team of assistants ready to provide a well-prepared meal for all the residents, especially those that need a special dietary. The workers at Sussex shows genuine concern about the health of the patients. Apart from taking care of the old, Sussex Healthcare invites adults suffering from various disorders like neurological conditions, learning disabilities, autism, and brain injuries. Thus, we have a noticeable understanding of the people who call Sussex home.

Early this year, the institution announced the appointment of a new Chief Executive Officer, Amanda Morgan-Taylor. Shortly after, the CEO acquainted herself with the situation around Sussex before beginning her role. Her first plan of action started by visiting all the homes around Sussex to interact with the residents, workers, and the community at large. Morgan-Taylor answered the various question on how she would handle issues at Sussex Healthcare within the role of her office. The core agenda of the leader is to co-operate accordingly with the rest of the administrative team to offer service improvement, quality of life, and compliance.

As a visionary leader, Morgan-Taylor works herself through leadership ranks to the current post. Initially, she worked as a managing director, service director, and quality development director. Thus, she sees through all the challenges her workers encounter. Moreover, the leader listens to different ideas from her employees and gives a chance to try them out. Therefore, Morgan-Taylor qualifies to provide professional medical care at Sussex Healthcare. The CEO began her career as a mental health nurse in 1984. The individual has more than 30 years of experience practicing in both the private and public healthcare arenas. The appointment of Amanda Morgan-Taylor to lead Sussex Healthcare showed a brighter life for the patients this year and in the future.


Dr. Clay Siegall is the President, Chief Executive Officer and Chairman of the Board of Directors at Seattle Genetics. Dr. Clay founded the company in 1998 with an objective of developing antibody-based cancer therapies. Seattle Genetics developed the first antibody-drug conjugate that was approved by the Food and Drug Administration in 2011 called ADCETRIS (brentuximab vedotin).

The company has developed more than 20 drugs and has gotten into strategic partnerships with manufacturers such as Genentech, Bayer, and Pfizer. Seattle Genetics has grown to become one of the biggest companies in cancer drugs research and has very experienced researchers in the biotech industry. The company is set to become a leader in cancer drug development through its numerous drugs that are in the development pipeline.

Dr. Siegall does not believe that the systematic chemotherapies are effective hence will be soon discarded. That is why his company is working very hard to develop therapies that are more efficient and cost-effective. He believes that in decades to come, chemotherapies will be a thing of the past and will be replaced by targeted therapy drug for cancer that is more tolerable and effective.

Dr. Clay Siegall developed an interest in cancer therapies when a member of his family was diagnosed with cancer. During the treatment, he noted that his family member nearly died not because of cancer but because of acute anaemia caused by chemotherapy. He learned other treatment options available include amputation or radical surgery. It is at this point that he vowed to himself to develop a cancer therapy that was more tolerable and effective.

The other reason he founded Seattle Genetics was partly to make money. He noted that while working with Bristol as a senior researcher, the patents that he worked on earned the company millions of money but all he got was a paycheck. He decided to be his boss and have his long hours of research patented in his name.

Dr. Siegall Clay has a Bachelor of Science in Zoology from the University of Maryland and also a Ph.D. in Genetics from George Washington University. He previously worked from 1991 to 1997 at Bristol-Myers Squibb Pharmaceutical Research Institute as well as National Cancer Institute from 1988 to 1991.